# Kineticos Ventures

> Kineticos Ventures is a VC fund backing Biotechnology and Health Care. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Morrisville, United States
- Total investments: 9
- Last investment: Sep 2024
- Lead investor: 56%
- Last updated: Aug 2026
- Website: https://kineticos.com/life-science-consulting-companies/venture-capital-consulting-firm/

Kineticos Ventures is a VC fund in Morrisville focused on Biotechnology and Health Care. Kineticos Ventures Invests in biotechs looking to disrupt how drugs are developed, diseases are diagnosed and patients are treated. We focus on the areas of greatest medical need: Oncology, Neurosciences, and Rare Diseases. We believe that disruptive technologies such as Cell and Gene Therapy, Gene Editing, mRNA/RNAi will dramatically changehow medicine is practiced.

## Contacts

5 contacts available for Kineticos Ventures. Shizune tracks 2 team members at Kineticos Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kineticos-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 67% |
| Health Care | 4 | 44% |
| Pharmaceutical | 3 | 33% |
| Life Science | 2 | 22% |
| Medical | 1 | 11% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 56% |
| Series B | 2 | 22% |
| Venture - Series Unknown | 2 | 22% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 56% |
| United Kingdom | 2 | 22% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Frank Lis | President and CEO | 3 | — |
| Shailesh Maingi | Founder & Exec Chair | 3 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Experic | Experic is a CMO and pharmaceutical supply services company, delivers advanced manufacturing, packaging, and labeling technologies. | $15M | Venture - Series Unknown | Sep 25, 2024 |  |
| Orthobond | Orthobond Corp. develops surface modification technology that can be applied to synthetic materials to produce biological responses. It offers a technology based on self-assembled monolayers of phosphonate (SAMP); and osteoconductive self-assembled monolayer of phosphonate surface modification that elicits a biological response on inorganicimplants without the use of a biologic. The company also provides bioresistant technology to address the need of tissue integration into permanent implants; and AI-SAMP anti-infective technology that helps in preventing a range of orthopedic infections by killing bacteria as they contact the pin surface and preventing biofilm formation, pre and post-operatively. Orthobond Corp. was founded in 2003 and is based in North Brunswick, New Jersey. |  | Venture - Series Unknown | Sep 09, 2024 |  |
| EnteroBiotix | EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $29.3M | Series B | Apr 04, 2024 |  |
| eXmoor Pharma | eXmoor Pharma is a technical and strategic consultancy specializing in cell and gene therapies (ATMPs) and biopharmaceuticals. | $35M | Series A | May 30, 2023 |  |
| Experic | Experic is a CMO and pharmaceutical supply services company, delivers advanced manufacturing, packaging, and labeling technologies. | $14M | Series B | Nov 30, 2022 |  |
| Inceptor Bio | Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers, with a focus on novel mechanisms to improve immune cell performance in the tumor microenvironment. Inceptor Bio provides a partnership model to university research programs focused on cutting-edge therapeutic approaches for oncology. The combination of their lab andmanufacturing resources with the industry experience of their cell and gene therapy experts will advance therapeutics into the clinic with remarkable efficiency. | $37M | Series A | May 19, 2022 |  |
| EnteroBiotix | EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $21.4M | Series A | Sep 07, 2021 |  |
| Kincell Bio | Kincell Bio collaborates with cell therapy developers by using considerable scientific experience and industry understanding. Transparency, accountability, and accuracy are essential to what makes us a reliable partner for process and analytical development, CMC assistance, and high-quality clinical cell therapy manufacturing services. | $36M | Series A |  |  |
| Clarametyx Biosciences | Clarametyx Biosciences is a late preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms. |  | Series A |  |  |

9 of 9 investments shown.

## Co-investors
- [East Seattle Partners](https://shizune.co/investors/profile/east-seattle-partners) — VC Fund, 2 deals together
- Harro Höfliger — VC Fund, 2 deals together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 2 deals together
- [Thairm Bio](https://shizune.co/investors/profile/thairm-bio) — VC Fund, 2 deals together
- 1315 Capital — VC Fund, 1 deal together
- [MVM Life Science Partners](https://shizune.co/investors/profile/mvm-life-science-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kineticos Ventures invest in?

Kineticos Ventures invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Kineticos Ventures?

Public channels for Kineticos Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Kineticos Ventures?

The team at Kineticos Ventures includes Frank Lis (President and CEO) and Shailesh Maingi (Founder & Exec Chair). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co